Latest Cytomedix Inc. New (CMXI) Headlines
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
W2 Energy Reports on 2013 and Looks Forward to 2014
Marketwire - Tue Jan 14, 1:06PM CST
W2 Energy, Inc. (OTC Pink: WTWO) is pleased to report on 2013's past year progress and looking forward into 2014.
Better Increase, Best Family, Fun Day for Eskom Workers [press release]
All Africa Global Media - Tue Jan 14, 12:38PM CST
The National Union of Mineworkers (NUM) is extremely saddened by Eskom for its failure to pay the salary increase of its employees "who have been unilaterally declared essential service by Eskom Management".
Cytomedix Announces Completion of RECOVER-Stroke Trial Enrollment and Update on Bright Cell Technology
Marketwire - Mon Jan 06, 7:02AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today the completed enrollment of the RECOVER-Stroke trial. Based on an interim resizing analysis that was performed on the existing population of all subjects who have reached the treatment plus 90 days primary efficacy endpoint, it was concluded that the ongoing RECOVER-Stroke trial is adequately powered based on pre-specified assumptions at the current enrollment of 48 patients. Consequently, additional screening and enrollment of new patient subjects will cease immediately. The Company expects to announce the top line clinical results in May 2014 when they become available.
Cytomedix Announces Final Payment Decision From the Centers for Medicare & Medicaid Services for the AutoloGel(TM) System
Marketwire - Mon Dec 02, 7:01AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today that the Centers for Medicare & Medicaid Services (CMS) has issued final Medicare payment regulations for the Hospital Outpatient Prospective Payment System (HOPPS) and the Medicare Physician Fee Schedule (MPFS), which allow for ample payment for use of the AutoloGel(TM) System for the treatment of chronic, non-healing wounds. These rules will take effect January 1, 2014.
Market Research: Lysosomal Storage Disorder - Pipeline Review, H2 2013
M2 - Wed Nov 20, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j39q2v/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H2 2013" report to their offering. 'Lysosomal Storage Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lysosomal Storage Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder. Scope - A snapshot of the global therapeutic scenario for Lysosomal Storage Disorder. - A review of the Lysosomal Storage Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lysosomal Storage Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Sangamo BioSciences, Inc. BioMarin Pharmaceutical Inc. Neuralstem, Inc. Amicus Therapeutics, Inc. Cytomedix, Inc. AngioChem Inc. Zymenex A/S Synageva BioPharma Corp. Fate Therapeutics, Inc. REGiMMUNE Corporation For more information visit http://www.researchandmarkets.com/research/j3...al_storage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cytomedix Reports Third Quarter 2013 Financial Results and Begins Supplying AutoloGel to Treat Medicare Patients
Marketwire - Tue Nov 12, 3:45PM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the third quarter of 2013 and announced the initiation of AutoloGel sales to treat Medicare beneficiaries under the Coverage with Evidence Development (CED) program and the Physician Fee Schedule (PFS).
Ischemic Stroke Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/bpg5ck/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. 'Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Athersys, Inc. - Merck & Co., Inc. - FibroGen, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Celgene Corporation - Neuralstem, Inc. - Cytomedix, Inc. - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - NeuroVive Pharmaceutical AB - SynZyme Technologies, LLC - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bp...mic_stroke
Cytomedix to Host Third Quarter 2013 Financial Results Conference Call on Wednesday, November 13, 2013
Marketwire - Tue Nov 05, 9:30AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and nine-month period ended September 30, 2013, after the close of the market on Tuesday, November 12, 2013.
Cytomedix Provides Update on Reimbursement Progress for AutoloGel(TM) in the Hospital Outpatient Prospective Payment System (HOPPS)
Marketwire - Wed Sep 18, 7:01AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet technologies, today provided an update on recent progress in attaining appropriate reimbursement for AutoloGel(TM) in the Medicare Hospital Outpatient Prospective Payment System (HOPPS). The Company has filed public comments with the Centers for Medicare and Medicaid Services (CMS) on the previously announced proposed rules for HOPPS and recently held a direct meeting with CMS. Based on these interactions, Cytomedix believes that CMS now has all the information required to make a final and fully informed decision on AutoloGel reimbursement in the hospital outpatient setting.
Cytomedix Announces Strategic Reorganization of Research and Development Operations
Marketwire - Tue Sep 17, 3:01PM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative cell based technologies, today announced that, in line with its strategy to build a profitable and successful company commercially focused on the wound care market, it will reorganize its research and development activities. As part of this initiative, the Company's ongoing financial support of the current RECOVER-Stroke trial and the underlying ALDH Bright Cell technology will be substantially concluded as of year-end 2013. The Company is exploring a range of strategic options for continuing its clinical programs beyond year-end 2013, which options may include, among others, technology transfer, spinout, licensing or other similar transactions involving the underlying technology.
OTC Daily Alert Stock Watch - Cytomedix, Inc (OTCQX: CMXI)
WorldStockWire - Fri Aug 16, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cytomedix Announces Second Quarter 2013 Financial Results and Commercial Partnership for Angel(R) Technology
Marketwire - Wed Aug 07, 6:35PM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet technologies, today released financial results for the second quarter of 2013 and announced a commercial licensing agreement for Angel(R) that provides for an upfront $5 million payment and an ongoing source of royalty income.
Cytomedix to Host Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
Marketwire - Fri Aug 02, 7:00AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that it will release financial results for the three- and six-month period ended June 30, 2013, after the close of the market on Wednesday, August 7, 2013.
Centers for Medicare and Medicaid Services Issues Proposed Payment Rules Affecting AutoloGel(TM) for Chronic Non-Healing Wounds
Marketwire - Wed Jul 10, 7:01AM CDT
Cytomedix, Inc. (OTCQX: CMXI)
Malignant Glioma - Pipeline Review, H1 2013 Reviews Key Players Involved in the Therapeutic Development
M2 - Fri Jun 07, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4x83jz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. Malignant Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - Coverage of products based on various stages of development ranging from disco
DAVID EMERSON. JORDEN of Cytomedix, Inc. (CMXI)-OTC BB bought Shares of CMXI
M2 - Wed May 22, 10:45AM CDT
Reported by InsiderCow.com at 2013-05-21 14:31:27 ET
WEALTHMAKERS.COM Issues Bullish Research Reports on CMXI, DHR, ETAK, EXAR, HSTM, HTLF
M2 - Fri May 17, 10:53AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Cytomedix Inc (OTC:CMXI), Danaher Corp (NYSE
HR), Elephant Talk Communications Inc (OTCBB:ETAK), Exar Corp (NASDAQ:EXAR), HealthStream Inc (NASDAQ:HSTM), Heartland Financial USA Inc (NASDAQ:HTLF)
Cytomedix to Present at the World Stem Cells & Regenerative Medicine Congress 2013
Marketwire - Fri May 17, 7:00AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Edward Field, the Company's Chief Operating Officer, has been invited to make a presentation on Partnering & Collaboration at the World Stem Cells & Regenerative Medicine Congress 2013, which will be held May 21-23, 2013 in London, United Kingdom.
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
W2 Energy Reports on 2013 and Looks Forward to 2014
Marketwire - Tue Jan 14, 1:06PM CST
W2 Energy, Inc. (OTC Pink: WTWO) is pleased to report on 2013's past year progress and looking forward into 2014.
Better Increase, Best Family, Fun Day for Eskom Workers [press release]
All Africa Global Media - Tue Jan 14, 12:38PM CST
The National Union of Mineworkers (NUM) is extremely saddened by Eskom for its failure to pay the salary increase of its employees "who have been unilaterally declared essential service by Eskom Management".
Cytomedix Announces Completion of RECOVER-Stroke Trial Enrollment and Update on Bright Cell Technology
Marketwire - Mon Jan 06, 7:02AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today the completed enrollment of the RECOVER-Stroke trial. Based on an interim resizing analysis that was performed on the existing population of all subjects who have reached the treatment plus 90 days primary efficacy endpoint, it was concluded that the ongoing RECOVER-Stroke trial is adequately powered based on pre-specified assumptions at the current enrollment of 48 patients. Consequently, additional screening and enrollment of new patient subjects will cease immediately. The Company expects to announce the top line clinical results in May 2014 when they become available.
Cytomedix Announces Final Payment Decision From the Centers for Medicare & Medicaid Services for the AutoloGel(TM) System
Marketwire - Mon Dec 02, 7:01AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today that the Centers for Medicare & Medicaid Services (CMS) has issued final Medicare payment regulations for the Hospital Outpatient Prospective Payment System (HOPPS) and the Medicare Physician Fee Schedule (MPFS), which allow for ample payment for use of the AutoloGel(TM) System for the treatment of chronic, non-healing wounds. These rules will take effect January 1, 2014.
Market Research: Lysosomal Storage Disorder - Pipeline Review, H2 2013
M2 - Wed Nov 20, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j39q2v/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H2 2013" report to their offering. 'Lysosomal Storage Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lysosomal Storage Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder. Scope - A snapshot of the global therapeutic scenario for Lysosomal Storage Disorder. - A review of the Lysosomal Storage Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lysosomal Storage Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Sangamo BioSciences, Inc. BioMarin Pharmaceutical Inc. Neuralstem, Inc. Amicus Therapeutics, Inc. Cytomedix, Inc. AngioChem Inc. Zymenex A/S Synageva BioPharma Corp. Fate Therapeutics, Inc. REGiMMUNE Corporation For more information visit http://www.researchandmarkets.com/research/j3...al_storage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cytomedix Reports Third Quarter 2013 Financial Results and Begins Supplying AutoloGel to Treat Medicare Patients
Marketwire - Tue Nov 12, 3:45PM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the third quarter of 2013 and announced the initiation of AutoloGel sales to treat Medicare beneficiaries under the Coverage with Evidence Development (CED) program and the Physician Fee Schedule (PFS).
Ischemic Stroke Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/bpg5ck/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. 'Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Athersys, Inc. - Merck & Co., Inc. - FibroGen, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Celgene Corporation - Neuralstem, Inc. - Cytomedix, Inc. - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - NeuroVive Pharmaceutical AB - SynZyme Technologies, LLC - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bp...mic_stroke
Cytomedix to Host Third Quarter 2013 Financial Results Conference Call on Wednesday, November 13, 2013
Marketwire - Tue Nov 05, 9:30AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and nine-month period ended September 30, 2013, after the close of the market on Tuesday, November 12, 2013.
Cytomedix Provides Update on Reimbursement Progress for AutoloGel(TM) in the Hospital Outpatient Prospective Payment System (HOPPS)
Marketwire - Wed Sep 18, 7:01AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet technologies, today provided an update on recent progress in attaining appropriate reimbursement for AutoloGel(TM) in the Medicare Hospital Outpatient Prospective Payment System (HOPPS). The Company has filed public comments with the Centers for Medicare and Medicaid Services (CMS) on the previously announced proposed rules for HOPPS and recently held a direct meeting with CMS. Based on these interactions, Cytomedix believes that CMS now has all the information required to make a final and fully informed decision on AutoloGel reimbursement in the hospital outpatient setting.
Cytomedix Announces Strategic Reorganization of Research and Development Operations
Marketwire - Tue Sep 17, 3:01PM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative cell based technologies, today announced that, in line with its strategy to build a profitable and successful company commercially focused on the wound care market, it will reorganize its research and development activities. As part of this initiative, the Company's ongoing financial support of the current RECOVER-Stroke trial and the underlying ALDH Bright Cell technology will be substantially concluded as of year-end 2013. The Company is exploring a range of strategic options for continuing its clinical programs beyond year-end 2013, which options may include, among others, technology transfer, spinout, licensing or other similar transactions involving the underlying technology.
OTC Daily Alert Stock Watch - Cytomedix, Inc (OTCQX: CMXI)
WorldStockWire - Fri Aug 16, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cytomedix Announces Second Quarter 2013 Financial Results and Commercial Partnership for Angel(R) Technology
Marketwire - Wed Aug 07, 6:35PM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet technologies, today released financial results for the second quarter of 2013 and announced a commercial licensing agreement for Angel(R) that provides for an upfront $5 million payment and an ongoing source of royalty income.
Cytomedix to Host Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
Marketwire - Fri Aug 02, 7:00AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that it will release financial results for the three- and six-month period ended June 30, 2013, after the close of the market on Wednesday, August 7, 2013.
Centers for Medicare and Medicaid Services Issues Proposed Payment Rules Affecting AutoloGel(TM) for Chronic Non-Healing Wounds
Marketwire - Wed Jul 10, 7:01AM CDT
Cytomedix, Inc. (OTCQX: CMXI)
Malignant Glioma - Pipeline Review, H1 2013 Reviews Key Players Involved in the Therapeutic Development
M2 - Fri Jun 07, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4x83jz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. Malignant Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - Coverage of products based on various stages of development ranging from disco
DAVID EMERSON. JORDEN of Cytomedix, Inc. (CMXI)-OTC BB bought Shares of CMXI
M2 - Wed May 22, 10:45AM CDT
Reported by InsiderCow.com at 2013-05-21 14:31:27 ET
WEALTHMAKERS.COM Issues Bullish Research Reports on CMXI, DHR, ETAK, EXAR, HSTM, HTLF
M2 - Fri May 17, 10:53AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Cytomedix Inc (OTC:CMXI), Danaher Corp (NYSE
HR), Elephant Talk Communications Inc (OTCBB:ETAK), Exar Corp (NASDAQ:EXAR), HealthStream Inc (NASDAQ:HSTM), Heartland Financial USA Inc (NASDAQ:HTLF) Cytomedix to Present at the World Stem Cells & Regenerative Medicine Congress 2013
Marketwire - Fri May 17, 7:00AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Edward Field, the Company's Chief Operating Officer, has been invited to make a presentation on Partnering & Collaboration at the World Stem Cells & Regenerative Medicine Congress 2013, which will be held May 21-23, 2013 in London, United Kingdom.
